MABWELL-B (HKEX: 02493) shares have surged more than 7% in today's trading session. At the time of writing, the stock is up 5.71%, trading at HK$25.9 with a turnover of HK$48.537 million.

Key Development

The catalyst for this upward movement is a significant regulatory milestone. On June 4th, the company announced that its self-developed novel antibody drug, the 9MW5211 injection, has officially received approval from China's National Medical Products Administration (NMPA) to conduct clinical trials for the treatment of Inflammatory Bowel Disease (IBD). This follows a prior clearance from the U.S. Food and Drug Administration (FDA) for the same drug candidate to proceed with IBD trials in the United States.

Pipeline and Future Catalysts

Analysts have highlighted several upcoming catalysts for the company's development pipeline. The Phase IIb clinical trial for its ST2 monoclonal antibody is currently in the patient enrollment stage, with efficacy data expected to be read out subsequently. Progress continues on the Phase III trials for its Nectin-4 ADC, including trials for urothelial carcinoma (UC) as a monotherapy, in combination, and for cervical cancer (CC) as a monotherapy, with an interim analysis anticipated in 2026. Furthermore, the company plans to submit applications for its LILRB4/CD3 T-cell engager (TCE) therapy in both China and the U.S. in the first half of 2026, with several other TCE projects targeting solid tumors expected to enter the pre-clinical stage soon. Potential business development (BD) activities also remain a point of focus for the company's future growth.